Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NM6603 in Patients With Advanced Solid Tumors

NCT07292038 is registered in ClinicalTrials.gov with NucMito Pharmaceuticals Co. Ltd. as lead sponsor.

NCT NCT07292038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07292038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NM6603 in Patients With Advanced Solid Tumors
Lead sponsor
NucMito Pharmaceuticals Co. Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
December 18, 2025
Completion date
November 30, 2026
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancers